研发加IP，医药公司发展壮大的好方法

CCPIT PATENT AND TRADEMARK LAW OFFICE is the oldest and one of the largest full-service intellectual property law firms in China. Our firm has 322 patent and trademark attorneys, among whom 93 are qualified as attorneys-at-law. We provide consultation, prosecution, mediation, administrative enforcement and litigation services relating to patents, trademarks, copyrights, domain names, trade secrets, trade dress, unfair competition and other intellectual property-related matters. headquartered in Beijing, we have branch offices in New York, Silicon Valley, Tokyo, Munich, Madrid, Hongkong, Shanghai，Guangzhou and Shenzhen.

Explore Firm Details

4月30日，百济神州公告表示，美国专利商标局（USPTO）近日作出决定，宣告Pharmacyclics公司持有的第11672803号美国专利（以下简称"803专利"）全部权利要求无效。

China Intellectual Property

Article Insights

Chen Xin’s articles from CCPIT Patent & Trademark Law Office are most popular:

within Intellectual Property topic(s)
with Senior Company Executives, HR and Finance and Tax Executives
in United States
with readers working within the Accounting & Consultancy, Healthcare and Oil & Gas industries

说及IP，也就是知识产权，要说最近可谓最大的与医药、与IP均相关的消息可能有两个，都与百济神州相关：

百济神州有限公司（纳斯达克代码：ONC；香港联交所代码：06160；上交所代码：688235）是一家全球肿瘤治疗创新公司，宣布新英文名称BeOne Medicines Ltd.,的启用以及注册地从开曼迁至瑞士的事项已正式生效，达成公司发展进程中的又一重要里程碑。
百济神州联合创始人、董事长兼首席执行官欧雷强先生表示，"百悦泽®作为公司血液肿瘤治疗的基石产品，取得了爆炸式增长；......新篇章伊始，我期待与大家一起以BeOne之名，携手共赴未来。"

两条消息的"主人公"都是百济神州公司，既然如此，我们就从相对熟悉的裁定开始分析吧。

请点击此处阅读文章正文。

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

[View Source]

研发加IP，医药公司发展壮大的好方法

Contributor

Intellectual Property

Contributor

China